Document is current
Any future updates will be listed below
-
Authors
Manzano, Sagrario
Maurino, Jorge https://orcid.org/0000-0001-9858-3555
Balasa, Mircea
Piñol-Ripoll, Gerard
Boada, Mercè
Landete, Lamberto
Abellán, Inmaculada
Berbel, Ángel
Espejo, Beatriz
Almagro, Mariló
Rodrigo, Jesús
Sánchez-Juan, Pascual
García-Arcelay, Elena
Ballesteros, Javier
-
Funding
Funding for this research was provided by:
Roche (ML44177)
- License Information
-
More Information
Article History
Received: 9 August 2025
Accepted: 16 October 2025
First Online: 8 November 2025
Declarations
:
: Sagrario Manzano and Pascual Sánchez-Juan received economic compensation from Roche, Almirall, Bayer, Biogen, Bristol-Myers Squibb, Sanofi-Genzyme, Merck, Novartis, UCB, and Teva. Mercè Boada reports receiving consulting fees from Grifols, Araclon Biotech, Roche, Biogen, Lilly, Merck, Zambon, and Novo Nordisk; holding advisory board memberships with Grifols, Roche, Lilly, Araclon Biotech, Merck, Zambon, Biogen, Novo Nordisk, Bioiberica, Eisai, Servier, and Schwabe Pharma; and receiving lecture fees from Roche, Biogen, Grifols, Nutricia, Araclon Biotech, Servier, and Novo Nordisk. Elena García-Arcelay and Jorge Maurino are employees of Roche Farma Spain. Mircea Balasa, Gerard Piñol-Ripoll, Lamberto Landete, Inmaculada Abellán, Angel Berbel, Beatriz Espejo, Mariló Almagro, Jesús Rodrigo, and Javier Ballesteros declared no conflicts of interest.
: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of Hospital Universitario del Mar in Barcelona, Spain. All participants provided written informed consent.
